Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Diazepam

FDA-approved product (tablet, oral), marketed as Diastat, Diastat Acudial, Diazepam and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Diazepam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Agitation
  • Anxiety
  • Anxiety disorder
  • Cerebral palsy
  • Epilepsy
  • Stiff-Person syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine derivatives
FDA pharmacologic class
Benzodiazepine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Diazepam in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Diazepam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients

    NCT00641797 · start 2006-11

    Registered record
    Registry ID
    NCT00641797
    Conditions
    Benign Paroxysmal Positional Vertigo
    Interventions
    Meclizine; Epley Maneuver; Lorazepam; Diphenhydramine; Ondansetron
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-11
    Completion
    2013-11
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Paroxysmal Positional Vertigo
    InterventionMeclizine; Epley Maneuver; Lorazepam; Diphenhydramine +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures

    NCT00326612 · start 2006-06

    Registered record
    Registry ID
    NCT00326612
    Conditions
    Seizures
    Interventions
    Midazolam; Diazepam
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-06
    Completion
    2008-12
    Enrolment
    358

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeizures
    InterventionMidazolam; Diazepam
    PhasePhase 2
    Registry statusCompleted

  • Excessive Crying in Children With Cerebral Palsy and Communication Deficits

    NCT04523935 · start 2005-12-07

    Registered record
    Registry ID
    NCT04523935
    Conditions
    Cerebral Palsy; Excessive Crying; Pain
    Interventions
    Placebo; Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-12-07
    Completion
    2020-08-04
    Enrolment
    131

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Palsy; Excessive Crying; Pain
    InterventionPlacebo; Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.
    PhasePhase 4
    Registry statusCompleted

  • Comparison Between Nurse-Administered Propofol Sedation and Diazemuls / Pethidine in Outpatient Colonoscopy

    NCT00566683 · start 2005-07

    Registered record
    Registry ID
    NCT00566683
    Conditions
    Colonoscopy
    Interventions
    diazemuls, pethidine; Propofol and Alfentanil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-07
    Completion
    2006-06
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColonoscopy
    Interventiondiazemuls, pethidine; Propofol and Alfentanil
    PhaseNot applicable
    Registry statusCompleted

  • The Effect of Valproate on Benzodiazepine Withdrawal Severity

    NCT00570219 · start 2005-02

    Registered record
    Registry ID
    NCT00570219
    Conditions
    Substance Withdrawal Syndrome
    Interventions
    valproate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-02
    Completion
    2008-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubstance Withdrawal Syndrome
    Interventionvalproate
    PhaseNot applicable
    Registry statusCompleted